FDA Class II Recall: Guardian Drug Co. Inc. Faces Nationwide Contamination Issue in Calcium Carbonate Antacids
Guardian Drug Co. Inc. has initiated a nationwide Class II recall for H.E.B Extra Strength Calcium Carbonate Antacid Tablets due to metallic particle contamination. This event, impacting NDC 37808-136-22, signals critical quality control failures. For procurement and regulatory leaders, this underscores the imperative for stringent supplier qualification and robust quality agreements to mitigate supply chain disruptions and brand reputation damage.
FDA Class II Recall: Metallic Contamination in Calcium Carbonate Antacids
Guardian Drug Co. Inc., based in Dayton, NJ, has initiated a voluntary, firm-initiated Class II recall for its H.E.B Extra Strength Calcium Carbonate Antacid Tablets. The specific product affected is Calcium Carbonate 750 mg, distributed under NDC 37808-136-22, with Lot #: 1276118 and an expiration date of JAN 2029. The recall, identified as D-0573-2026, was initiated on May 28, 2026, and classified by the FDA on June 3, 2026. The critical reason for this recall is the confirmed presence of small metallic particles within the chewable tablets, posing a significant foreign substance risk. This nationwide distribution pattern means that the affected product could be present across the entire U.S. market, necessitating immediate action from distributors and retailers. For procurement directors and supply chain VPs, this event signals a direct threat to product integrity and consumer safety, demanding an urgent review of all incoming shipments from Guardian Drug Co. Inc. and a reassessment of quality control protocols for over-the-counter (OTC) antacid products. The Class II classification indicates that the use of, or exposure to, the contaminated product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This assessment by the FDA underscores the potential for patient harm, impacting brand trust for both Guardian Drug Co. Inc. and its downstream partners like H.E.B.
Immediate Business Impact: Supply Chain Disruption and Brand Risk
The nationwide Class II recall of H.E.B Extra Strength Calcium Carbonate Antacid Tablets by Guardian Drug Co. Inc. presents immediate and substantial business implications for all stakeholders. For procurement teams, this necessitates an urgent audit of all Calcium Carbonate 750 mg supplies sourced from Guardian Drug Co. Inc. to identify and quarantine affected lots (Lot #: 1276118). Failure to do so could result in further regulatory enforcement, costly product returns, and potential legal liabilities. Supply chain VPs must immediately assess inventory levels and distribution channels to understand the full scope of exposure and potential stockouts for this widely used OTC antacid. The recall's 'ongoing' status suggests that the full impact and resolution timeline are still unfolding, requiring continuous monitoring. Furthermore, this event carries significant brand reputation risk, not only for Guardian Drug Co. Inc. but also for H.E.B, whose name is prominently featured on the recalled product. Business development executives should anticipate questions from retail partners and consumers regarding product safety and quality assurance. This incident highlights the critical need for robust supplier qualification processes and comprehensive quality agreements that include clear specifications for foreign matter exclusion and rigorous testing protocols to prevent such contaminations from reaching the market. The financial implications extend beyond direct recall costs to potential loss of market share and increased scrutiny from regulatory bodies and consumers.
Broader Regulatory Environment: A Trend of Quality Control Challenges
This recall by Guardian Drug Co. Inc. is not an isolated incident but rather reflects a concerning trend of manufacturing quality control challenges within the pharmaceutical and life sciences sectors. Recent parallel events underscore this pattern: Essential Wellness Pharma faced a Class II recall for Progesterone Injection due to sterility assurance failures on June 15, 2026, and Spectra Medical Devices initiated a Class II recall for Lidocaine HCl Injection, also due to sterility deficiencies, on June 10, 2026. Even a Class III recall for Lidocaine HCl Injection by Eugia US LLC on June 10, 2026, due to labeling issues, points to systemic vulnerabilities. While the specific nature of the contamination differs, the common thread for regulatory affairs heads is the heightened scrutiny by the FDA on manufacturing practices, particularly concerning product integrity and safety. These events signal that regulatory bodies are actively enforcing Good Manufacturing Practices (GMP) and are quick to act on deviations that compromise patient safety. For companies operating in this space, this means that the regulatory bar for quality assurance is continuously rising. Proactive investment in advanced detection technologies for foreign substances, enhanced process controls, and comprehensive employee training programs are no longer optional but essential to maintain compliance and avoid costly recalls. The cumulative effect of these recalls across various companies indicates a need for industry-wide re-evaluation of quality management systems.
Remediation Requirements and Future Compliance Outlook for Guardian Drug Co. Inc.
As a voluntary, firm-initiated recall, Guardian Drug Co. Inc. is responsible for executing a comprehensive remediation plan under FDA oversight. The 'ongoing' status of recall D-0573-2026 indicates that the firm is actively working to remove the affected H.E.B Extra Strength Calcium Carbonate Antacid Tablets from distribution and address the root cause of the metallic particle contamination. Regulatory affairs heads must ensure Guardian Drug Co. Inc. conducts a thorough investigation into the origin of these foreign substances, implements corrective and preventive actions (CAPA), and verifies their effectiveness. This typically involves a detailed analysis of manufacturing equipment, raw material sourcing, and production processes. Failure to adequately address the underlying quality system deficiencies could lead to escalated FDA enforcement actions, including potential Warning Letters, import alerts for any international facilities, or even consent decrees. For business development executives, the ability of Guardian Drug Co. Inc. to demonstrate robust remediation and restore confidence in its quality systems will be crucial for future contract manufacturing opportunities and maintaining existing client relationships, particularly with major retailers like H.E.B. The market will closely watch for evidence of sustained compliance and improved product quality from their Dayton, NJ facility.
Strategic Risk Mitigation for Procurement and Supply Chain Leaders
In light of Guardian Drug Co. Inc.'s nationwide Class II recall for Calcium Carbonate 750 mg, procurement directors and supply chain VPs must implement proactive strategies to mitigate similar risks. First, diversify your supplier base for critical raw materials and finished drug products like Calcium Carbonate. Relying on a single source, especially one with a recent recall, exposes your business to unacceptable supply chain vulnerabilities. Second, enhance your supplier qualification and auditing programs. This must go beyond initial assessments to include regular, unannounced audits focusing on foreign matter control, equipment maintenance, and quality management systems. Third, establish stringent quality agreements that clearly define acceptable quality limits, testing methodologies, and notification protocols for any deviations. Fourth, invest in robust internal quality control measures, including incoming material inspection and in-process checks, to act as a secondary safeguard against supplier failures. While specific alternative suppliers for Guardian Drug Co. Inc. are not provided in the knowledge graph, companies such as Tishcon Corp., based in Salisbury, MD, and Pharmavite LLC, with facilities in Opelika, AL, are known manufacturers of dietary supplements and OTC products that could potentially offer Calcium Carbonate-based formulations, warranting further investigation for qualification. Proactive risk management is paramount to safeguarding product supply, maintaining regulatory compliance, and protecting brand equity in a volatile regulatory landscape.